Dr Nicky Levitt
MA, MB, BCh, DPhil, FRCP, Consultant Medical Oncologist
Languages spoken
English
Expert in
Breast cancer
Overview
Dr Nicky Levitt has been a Consultant in Medical Oncology since 2005, specialising in the treatment of breast cancer. She treats all types of breast cancer both in the early and metastatic settings, as well as prescribes systemic treatments, including chemotherapy, hormonal therapy and targeted therapies. Dr Levitt runs several clinical research trials and has various management roles as well as her own clinical practice in the NHS.
Current position(s)
- Consultant Medical Oncologist, Oxford
- Breast cancer in the early and metastatic settings
- Clinical trials
- Royal College of Physicians
- Association of Cancer Physicians
- UK Breast Cancer Group
- Shaveta Mehta, Nicholas P. Hughes, Francesca M. Buffa, Sonia P. Li, Rosemary F. Adams, Asha Adwani, N. Jane Taylor, Nicola C. Levitt, Anwar R. Padhani, Andreas Makris, Adrian L. Harris. Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. J Natl Cancer Inst Monogr 2011; 43: 71-74
- O.A. Khan, M. Ranson, M. Michael, I. Olver, N.C. Levitt, P. Mortimer, A.J. Watson, G.P. Margison, R. Midgley and M. Middleton. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. British Journal of Cancer 98 p1614-1618 (2008)
- Nicola C. Levitt, David J. Propper, Srinivasan Madhusudan, Jeremy P. Braybrooke, Chikodi Echeta, Robert te Poele, Sally Davies, Elizabeth Flanagan, Ian D. Hickson, Simon Joel and Trivadi S. Ganesan. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer British Journal of Cancer 93 (1) p60-69 (2005)
- Jeremy P. Brayebrooke, Nicola C. Levitt, Simon Joel, Theresa Davies, Srinivasan Madhusudan, Helen Turley, Sue Wilner, Adrian L. Harris and Denis C. Talbot. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIa expression Clinical Cancer Research 9 p4682-4688 (2003)
- N.C. Levitt, F.A.L.M. Eskens, K. J. O’Byrne, D.J. Propper, L.J. Denis, S.J. Owen, L. Choi, J.A. Foekens, S. Wilner, J. M. Wood, M. Nakajima, D.C. Talbot, W. P. Steward, A.L. Harris and J. Verweij. Phase I And Pharmacological Study Of The Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A) In Patients With Advanced Solid Cancer Clinical Cancer Research 7 p1912-1922 (2001)